CHICAGO, Jan. 23 /PRNewswire/ -- A new pharmaceutical company named BrianT Laboratories LLC headquartered in Lake Forest, IL, USA has been formed with Brian Tambi as Chairman, CEO and President, a group of health care investors announced today.
The firm has commenced operations to pursue and fund collaborative ventures to develop specialty pharmaceutical solid dose forms, and in-license late stage drug products. Brian T. Labs will market the products in the United States and, with its partners, in the rest of the world.
"We are also searching for equity investment in, or to acquire, a small ongoing company which can be used as a platform to manage our new product development programs, file our marketing applications and commercialize the company's drug products in the United States," Tambi said.
"Our first initiative is to complete ongoing drug development negotiations with two leading Indian pharmaceutical companies. We are focusing on expertise and capabilities in certain technologies including drug delivery systems that add therapeutic value and competitive advantage," Tambi said.
"Thus, the mission of BrianT Laboratories is to pursue and build a portfolio of drug products that represent technological improvement, added marketable therapeutic benefits and physician/patient preferences. Obviously, these are longer term efforts. Besides being investors, we have spent most of our long pharmaceutical careers in the best ethical and generic companies and have demonstrated success in building pharmaceutical businesses. The focus will be on adequate, consistent and long term investments in embedding technologies in drug formulations. I am very excited with another opportunity to pursue a new platform in pharmaceutical business development," he said.
Tambi left Morton Grove Pharmaceuticals after nearly 11 years as its Chairman, President and CEO. He has agreed to continue as non-executive Chairman of the Board. Tambi and William Blair Capital Partners bought MGP in 1995 when it was a small private label manufacturer and built it to become the market leader in manufacturing marketing and selling oral liquid prescription drugs under its own MGP label.
MGP was sold to and recapitalized by affiliates of GTCR Golder Rauner LLC and Tambi in February 2003. Thereafter, he structured a substantive R&D capability in developing new liquid formulations of leading solid oral drugs and controlled release liquid drugs.
Prior to MGP, in 1986 Tambi built the ethical division of LyphoMed in two years which sold for $850 million in 1989. He then established and headed Fujisawa Pharmaceutical Company USA in 1990. Tambi began his pharmaceutical career at Bristol-Myers where he spent 13 years in various management positions.
BrianT Laboratories LLCCONTACT: Brian Tambi, +1-847-615-0544, or Herb Kraus +1-312-578-9114, bothfor BrianT Laboratories LLC
